Generalized Anxiety Disorder Drug Pipeline: 13 Assets by Phase

How many generalized anxiety disorder drugs are in each phase of development?

Douglas Insights counts 7 generalized anxiety disorder candidates in Phase III, 54% of the 13 assets in development; Phase II holds 5 and Phase I holds 1.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each generalized anxiety disorder asset appears in exactly one row. The 28 trials still recruiting or running carry 45% of the 62 registered trials in scope.

How many generalized anxiety disorder trials are recruiting patients now?

16 generalized anxiety disorder trials are recruiting patients and 7 more have not started recruiting yet, out of 62 interventional trials in scope; together they make up 37% of the trial base.

Terminated, suspended and withdrawn generalized anxiety disorder trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the generalized anxiety disorder pipeline?

Otsuka Pharmaceutical Development & Commercialization, Inc. leads the generalized anxiety disorder pipeline with 2 candidates; the top 5 sponsors hold 46% of the 13 assets, and 12 sponsors run at least one.

Industry sponsors lead 33 of the 62 generalized anxiety disorder trials (53%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the generalized anxiety disorder pipeline?

Mechanism and drug-type classification for the 13 generalized anxiety disorder candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What generalized anxiety disorder trial readouts are coming next?

4 generalized anxiety disorder candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many generalized anxiety disorder readouts fall in each quarter?

4 generalized anxiety disorder candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 2, due in Q1 2027.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most generalized anxiety disorder trials?

United States hosts the most generalized anxiety disorder trials, with sites in 36 of the 62 studies (58%); trials in scope run in 24 countries in all.

A multinational generalized anxiety disorder trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are generalized anxiety disorder drugs being tested?

36 of the 62 generalized anxiety disorder trials (58%) have a site in the United States, 10 (16%) in Europe and 7 (11%) in China; 9 of the 13 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational generalized anxiety disorder trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the generalized anxiety disorder pipeline since the last update?

This is the first edition of the generalized anxiety disorder pipeline count, dated 4 Oct 2026. The next refresh is due by 2 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the generalized anxiety disorder pipeline?

Douglas Insights read 62 interventional trials registered on ClinicalTrials.gov for the conditions "Generalized Anxiety Disorder" and updated since 4 Oct 2021, then grouped every drug or biologic named in them into 13 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the generalized anxiety disorder pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage